Ghemaxan

Ghemaxan is a biosimilar of enoxaparin sodium, a low molecular weight heparin (LMWH) developed and produced by the Italfarmaco Group. It functions as an anticoagulant and antithrombotic agent by binding to and potentiating the activity of antithrombin III, which subsequently inhibits clotting factors, primarily Factor Xa and, to a lesser extent, Factor IIa (thrombin). Ghemaxan is indicated for the prophylaxis of venous thromboembolism (VTE) in surgical and non-surgical patients, the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), the prevention of thrombus formation during hemodialysis, and the treatment of acute coronary syndromes, including unstable angina and non-ST-elevation myocardial infarction (NSTEMI). The drug is administered via subcutaneous or intravenous injection and is manufactured in a GMP-certified facility in Milan, Italy.

Brand names

Ghemaxan

Other names

enoxaparin sodium